Retatrutide 15MG
£87.99
Retatrutide 15MG is a mid-strength synthetic multi-receptor peptide studied in research environments for its potential role in metabolic regulation and hormonal pathway analysis. Supplied in lyophilized form for laboratory research use only.
📄 Click Here To See The Certificate
- Studied for its potential role in triple receptor activation involving GIP, GLP-1, and glucagon receptors.
- Investigated in laboratory research involving glucose metabolism, energy expenditure, and metabolic regulation.
- Commonly used in studies of appetite regulation, body composition, and endocrine signaling.
- Explored for its effects on weight management and mitochondrial energy pathways.
| Product Name | BAC Water Volume | Final Concentration |
|---|---|---|
| Retatrutide (15 mg) | 1.5–3 mL | 5–10 mg/mL |
For research use only. Dilution volumes are provided as reference information and should be evaluated according to the specific research protocol.
- Active Compound: Retatrutide
- Strength: 15mg
- Purity: ≥99% (HPLC Tested)
- Form: Lyophilised Powder
- 1 × Sterile vial containing Retatrutide 15mg
- Tamper-evident protective cap
- Lyophilised powder for laboratory reconstitution
- Secure protective packaging
- Compound Name: Retatrutide
- Peptide Sequence: Modified 39-amino acid synthetic peptide with a C20 fatty diacid side chain for extended activity.
- Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
- Molecular Weight: 4,731.33 g/mol
- Chemical Classification: Triple GIP, GLP-1, and Glucagon Receptor Agonist (Tri-Agonist) Synthetic Peptide
Related products
FOXO4-DRI 10mg
Ipamorelin 5mg
PT-141 10MG
PT-141 (Bremelanotide) 10mg is a premium melanocortin receptor agonist peptide widely researched for its effects on libido, arousal signaling, and central nervous system pathways. Unlike traditional vascular-focused compounds, PT-141 is studied for its interaction with melanocortin receptors linked to desire and behavioral response mechanisms. Supplied as a high-purity 10mg lyophilized peptide for laboratory research use only.
